MyEcoCost - forming the nucleus of a novel environmental accounting system: vision, prototype and way forward

The innovative software system "myEcoCost" enables to gather and communicate resource and environmental data for products and services in global value chains. The system has been developed in the consortium of the European research project myEcoCost and forms a basis of a new, highly automated environmental accounting system für companies and consumers. The prototype of the system, linked to financial accounting of companies, was developed and tested in close collaboration with large and small companies. This brochure gives a brief introduction to the vision linked to myEcoCost: a network formed by collaborative environmental accounting nodes collecting environmental data at each step in a product's value chains. It shows why better life cycle data are needed and how myEcoCost addresses and solves this problem. Furthermore, it presents options for a future upscaling of highly automated environmenal accounting for prodcuts and services

Interferon γ–Induced Human Guanylate Binding Protein 1 Inhibits Mammary Tumor Growth in Mice

Interferon γ (IFN-γ) has recently been implicated in cancer immunosurveillance. Among the most abundant proteins induced by IFN-γ are guanylate binding proteins (GBPs), which belong to the superfamily of large GTPases and are widely expressed in various species. Here, we investigated whether the well-known human GBP-1 (hGBP-1), which has been shown to exert antiangiogenic activities and was described as a prognostic marker in colorectal carcinomas, may contribute to an IFN-γ–mediated tumor defense. To this end, an IFN-independent, inducible hGBP-1 expression system was established in murine mammary carcinoma (TS/A) cells, which were then transplanted into syngeneic immune-competent Balb/c mice. Animals carrying TS/A cells that had been given doxycycline for induction of hGBP-1 expression revealed a significantly reduced tumor growth compared with mock-treated mice. Immunohistochemical analysis of the respective tumors demonstrated a tightly regulated, high-level expression of hGBP-1. No signs of an enhanced immunosurveillance were observed by investigating the number of infiltrating B and T cells. However, hemoglobin levels as well as the number of proliferating tumor cells were shown to be significantly reduced in hGBP-1–expressing tumors. This finding corresponded to reduced amounts of vascular endothelial growth factor A (VEGF-A) released by hGBP-1–expressing TS/A cells in vitro and reduced VEGF-A protein levels in the corresponding mammary tumors in vivo. The results suggest that hGBP-1 may contribute to IFN-γ–mediated antitumorigenic activities by inhibiting paracrine effects of tumor cells on angiogenesis. Consequently, owing to these activities GBPs might be considered as potent members in an innate, IFN-γ–induced antitumoral defense system